The alternative pathway of complement in disease: opportunities for therapeutic targeting

被引:74
作者
Holers, VM
Thurman, JM
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA
关键词
complement; alternative pathway; animal models; inflammation; therapeutics;
D O I
10.1016/j.molimm.2004.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The alternative pathway of complement is receiving increasing attention as a therapeutic target because of recent findings in several animal models that support its essential role in tissue injury and disease pathogenesis. Although the contribution of alternative pathway activation to serum complement activation in vitro is relatively modest, its role in generating activated pro-inflammatory fragments at extra-vascular sites is substantial. Several potential mechanisms might underlie this exaggerated effect, including local synthesis of alternative pathway components, disease-induced alterations of regulatory proteins, and influx of inflammatory cells that contain alternative pathway components into sites of injury. This review examines several animal models in which the alternative pathway is centrally involved in disease pathogenesis and which suggest a potential role for alternative pathway inhibitors as therapies for human disease. It is also expected that several clinically relevant studies will be presented at the XXth International Complement Workshop that will identify additional areas of interest with regard to this pathway. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:147 / 152
页数:6
相关论文
共 55 条
[1]   Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Kraus, DM ;
Hack, BK ;
Rakstang, JK ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (03) :670-679
[2]   Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Boackle, SA ;
Kraus, DM ;
Cunningham, PN ;
Park, P ;
Alexander, JJ ;
Anderson, RK ;
Culhane, K ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3601-3607
[3]  
Carroll M C, 2000, Adv Immunol, V74, P61
[4]   At the innate frontiers between mother and fetus: Linking abortion with complement activation [J].
Caucheteux, SM ;
Kanellopoulos-Langevin, C ;
Ojcius, DM .
IMMUNITY, 2003, 18 (02) :169-172
[5]   Effects of complement factor D deficiency on the renal disease of MRL/lpr mice [J].
Elliott, MK ;
Jarmi, T ;
Ruiz, P ;
Xu, YY ;
Holers, VM ;
Gilkeson, GS .
KIDNEY INTERNATIONAL, 2004, 65 (01) :129-138
[6]   Elements of immunity - The instructive role of innate immunity in the acquired immune response [J].
Fearon, DT ;
Locksley, RM .
SCIENCE, 1996, 272 (5258) :50-54
[7]   Complement in allergy and asthma [J].
Gerard, NP ;
Gerard, C .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (06) :705-708
[8]  
Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI18817
[9]   Complement deficiency ameliorates collagen-induced arthritis in mice [J].
Hietala, MA ;
Jonsson, IM ;
Tarkowski, A ;
Kleinau, S ;
Pekna, M .
JOURNAL OF IMMUNOLOGY, 2002, 169 (01) :454-459
[10]   The complement system as a therapeutic target in autoimmunity [J].
Holers, VM .
CLINICAL IMMUNOLOGY, 2003, 107 (03) :140-151